Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards
Human Brain Mapping · 2024-03 · 45 (4)
DOI: 10.1002/hbm.26645 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Brain Mapping, online erschienen am 06.03.2024. Verfasst von Claudia Massaccesi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Health Psychology, University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Narcotic Antagonists, Dopamine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vienna Science and Technology Fund.
Abstract (Originalsprache)
Rewards are a broad category of stimuli inducing approach behavior to aid survival. Extensive evidence from animal research has shown that wanting (the motivation to pursue a reward) and liking (the pleasure associated with its consumption) are mostly regulated by dopaminergic and opioidergic activity in dedicated brain areas. However, less is known about the neuroanatomy of dopaminergic and opioidergic regulation of reward processing in humans, especially when considering different types of rewards (i.e., social and nonsocial). To fill this gap of knowledge, we combined dopaminergic and opioidergic antagonism (via amisulpride and naltrexone administration) with functional neuroimaging to investigate the neurochemical and neuroanatomical bases of wanting and liking of matched nonsocial (food) and social (interpersonal touch) rewards, using a randomized, between‐subject, placebo‐controlled, double‐blind design. While no drug effect was observed at the behavioral level, brain activity was modulated by the administered compounds. In particular, opioid antagonism, compared to placebo, reduced activity in the medial orbitofrontal cortex during consumption of the most valued social and nonsocial rewards. Dopamine antagonism, however, had no clear effects on brain activity in response to reward anticipation. These findings provide insights into the neurobiology of human reward processing and suggest a similar opioidergic regulation of the neural responses to social and nonsocial reward consumption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Health Psychology, University of Vienna, Vienna, Austria.
- Department of Cognition, Emotion and Methods in Psychology, University of Vienna, Vienna, Austria.
- Department of Psychology, University of Essex, Colchester, UK.
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- MR Center of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Claudia Massaccesi, Christian Windischberger
Förderung
- Vienna Science and Technology Fund
Zitieren
APA
Massaccesi, C., Korb, S., Götzendorfer, S., Chiappini, E., Willeit, M., Lundström, J. N., Windischberger, C., Eisenegger, C., & Silani, G. (2024). Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards. Human Brain Mapping, 45(4). https://doi.org/10.1002/hbm.26645
Vancouver
Massaccesi C, Korb S, Götzendorfer S, Chiappini E, Willeit M, Lundström JN, et al. Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards. Human Brain Mapping. 2024;45(4). doi:10.1002/hbm.26645
BibTeX
@article{Massaccesi2024,
author = {Massaccesi, Claudia and Korb, Sebastian and Götzendorfer, Sebastian and Chiappini, Emilio and Willeit, Matthaeus and Lundström, Johan N and Windischberger, Christian and Eisenegger, Christoph and Silani, Giorgia},
title = {Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards},
journal = {Human Brain Mapping},
year = {2024},
volume = {45},
number = {4},
doi = {10.1002/hbm.26645}
}
EUVIMED